Last reviewed · How we verify
TY101
At a glance
| Generic name | TY101 |
|---|---|
| Sponsor | Tayu Huaxia Biotech Medical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory Lymphomas (PHASE1, PHASE2)
- Far Infrared Therapy on Peritoneal Function of CAPD Patients (PHASE3)
- Far Infrared Therapy on AV Fistula Flow, Endothelial Function and Echocardiography in ESRD Patients (PHASE4)
- Far Infrared Therapy on Peripheral Artery Disease in Hemodialysis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TY101 CI brief — competitive landscape report
- TY101 updates RSS · CI watch RSS
- Tayu Huaxia Biotech Medical Group Co., Ltd. portfolio CI